This week on The Genetics Podcast, Patrick is joined by Benny Sorensen, CEO of Hemab Therapeutics. They discuss how Hemab is reimagining clotting therapies by centering patient voices, how persistence and being “unreasonable” led to their first program, and the value of their multi-modality and collaborative approach.
Show Notes:
0:00 Intro to The Genetics Podcast
00:59 Welcome to Benny
01:49 Reimagining blood clotting therapies by listening to lived experience and embracing the biotech revolution
04:27 How persistence and patient voices sparked Hemab’s first drug development program
07:13 Overview of Glanzmann Thrombasthenia (GT) and Hemab’s antibody-based approach
10:09 Evolution of hemophilia treatment and neglected blood clotting disorders
14:18 Genetic and gender considerations around bleeding disorders
17:41 Hemab’s range of therapeutic modalities and the value of collaboration
21:00 Why deep domain expertise drives Hemab’s strategy and success
22:55 Lessons from the drug development process
24:16 Global insights into gender bias, health inequality, and bleeding disorder care
26:46 Upcoming milestones at Hemab
29:52 Lessons from running natural history studies to capture the patient experience
33:25 Redefining the patient journey through data
34:40 How Benny’s experience at Alnylam Therapeutics shaped his “unreasonable” leadership
38:16 Reflections on being a father and a CEO
40:38 Closing remarks and Benny’s commitment to thoughtful drug development
Find out more
Hemab Therapeutics (https://www.hemab.com/)
Hemab trial register (https://shorturl.at/8AAQN)
Please consider rating and reviewing us on your chosen podcast listening platform!
https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
